Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

Executive Summary

The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.

You may also be interested in...

Bruised Roche Wins Another UK Perjeta Round With Price Cut

In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.

Scottish HTA Finally OKs Roche’s Perjeta For Metastatic Breast Cancer

The Scottish health technology assessment body, the SMC, has recommended a number of products for funding under NHS Scotland: Roche’s breast cancer drug Perjeta, Pfizer’s Xeljanz for psoriatic arthritis, and two antidiabetics, MSD’s Steglatro (ertugliflozin) and Novo Nordisk’s Ozempic (semaglutide).


NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer

After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts